W welcome to alpha wolf trading do you know that there's over 12,000 stocks or companies that trade on the OTC between the NASDAQ and the New York Stock Exchange you have over 7,000 companies but us as retail investors we wouldn't know that unless we were researching because why Wall Street focuses on the elite the big companies and where the retail ADV investor has their advantage is in small and micro cap stocks why because you have the opportunity to speak directly with leadership that is what this is all about here at alpha wolf trading we're trying
to find the hidden gems and we interview the executive teams of companies that we think meet their parameters to be those hidden gems I also want to make sure you understand that this is not a paid for promotion I collect no compensation for the interviews I do here these companies that I interview have been identified as potential opportunities for me and the members of alpha wolf trading to receive a higher than average return on our investment these companies I have identified either because of a technical setup on a chart a fundamental change within the organization
new management team new products all kinds of different things that actually lead me here but what do I think is the most important lead leadership and that is why I do these interviews I want to understand what drives the person that is leading the charge I want to feel their passion I want to understand their vision and the strategy that they're going to use to achieve success that is what these interviews are for I want to understand the share structure and the cap table the size of the Tam the total addressable Market this is the
opport Unity to learn all of those things so sit back and enjoy and if you learn anything from today's interview do us a favor subscribe to the alpha wolf trading YouTube channel this video is for educational and entertainment purposes only I am not a financial advisor I recommend highly that before buying any security speak to a financial advisor and do your own due diligence okay hey everybody Tim from alpha trading coming at you with a follow-up interview uh which has taken a while and there's a reason for that Ro because Robert Hayes the uh CEO
over at Sharps has been working on lots of different things and there have been some um there have been some some obstacles right Robert Yeah Tim there's been some challenges but I think this time we were able to to work through those in a collaborative way with nefron to to get this done all right so let's you just had a big announcement um and you filed an 8K that also has some pretty interesting stuff in there and I think this is turning into a pretty exciting time for Sharp's uh Technologies yeah it's a it's really
a transformative time um for sharps through the partnership that we're going to form with nefron as part of this pre-filled syringe operation in in South Carolina so we've had the opportunity to know Bill and Luke Kennedy who owned nefron for a few years now and um really great people a great operation you know they've gone through some challenges of their own but you know the partnership that that we plan to form with them will be a long-term uh situation you know where we're going to make the the pre buil syringes for them for their 503b
and generic drug manufacturing operation there in in in Colombia and uh allow us to have the first specialized uh co-polymer pre-fill syringe plant in the United States to not only service nefron and other generic drug manufacturers but also branded and specialy Pharma products uh and we're actually going to focus on a lot of the glp1 opportunities that are there for the diabetes Market Market in the weight loss Market through Lily and through Nova nordis okay so so this is almost like the perfect storm because you have uh some quality control issues uh coming out of
China y that have uh created a a nice opportunity for you not to mention the Biden Administration imposing a 50% tariff yep exactly right so you know when you look at at syringes and Drug delivery um devices in the market you have many different types and China has always been a large producer of what we call um plastic syringes or syringes that work with h vile um uh dispensing so these are single-use medical devices typically made out of polypropylene that have a needle attached and China was uh and has been historically a large producer uh
what'll happen is US companies will bring those in under private label and then sell those in the the US market and then you actually have a lot of us companies that have Manufacturing in China uh for some of their products that they bring back to the us so you know the quality issues were called out um recently for for a lot of the major companies that have been doing this for a while uh there's been warning letters put out and then like you said most recently the Biden Administration has re recognize some of the um
challenges that that us um companies have competing with China and have imposed uh 50% tariffs to go in place against products that are made in China and then brought into the United States so this creates a huge opportunity not only for sharps uh for those products but for other companies that produce products here in the United States or in other countries outside of China to allow us to be very competitive so we see this is a great opportunity not only the the deal with um nefron that we're going to talk about but um the the
the specialized plastic syringe Market segment it's going to be a huge opportunity for us and others to to gain market share and take over opportunities and then you also uh announced a partnership yep that is out of Italy right yep yep so we um we have um worked with ronad Deli who is a privately held um medical device syringe manufacturing company based out of Italy they make similar products um to ours that are complimentary um in the the plastic syringe space and so we announced a partnership to to co-sell our products and and their products
and to leverage their sales and distribution channels in Europe and rest of world so the the agreement is a huge opportunity for us to expand the portfolio to include active safety syringes um syringes without needle um like your secure guard your solo guard and then also bring in this passive safety technology that safer has uh that ronad Deli has um developed under the safer brand and so the safer brand is the the technology that we're really excited about passive safety syringes are very popular in the United States so we see a huge opportunity to introduce
these products through the the collaboration that we have with ronad Deli now so um hungry with the factory in Hungary they would be a big beneficiary of of the Chinese deal right absolutely yeah hungary's a great um Technology Center for syringes BD has manufacturing there we have manufacturing there and so this facility um will be key for us to allow us to now take over and gain market share as a result of the news that that we kind of summarized for our investors yesterday through the press release but you know the the Hungary facility and
and the the facility in Italy for ronad Deli that we're working with will both benefit from from these new opportunities for sure okay and then I don't know if everybody can see this but this beautiful building here yep that has a big old sharp Side Up in the corner yeah it's really exciting it's a rendering of the facility that we're under agreement now to purchase from um Bill and Luke Kennedy it's the inject EZ operation that they started a few years back uh that we've been working uh on with them um that's the opportunity for
us to buy this facility um that's in the the 8K that was filed last Friday so the opportunity now really you know um was re worked over the end of the year coming into the front part of 24 to really benefit both sides so we are getting what I consider to be a better deal on the operation so we're going to purchase the facility assets for about $35 million um and then as part of that purchase um we're going to have a five-year agreement with nefron to be exclusive supplier for their co-polymer syringes for their
filling operation about 2 mil down the road so you know the original agreement was was $50 million for the the building and then we were going to upgrade the building and be pretty much focused on on nefron where this new agreement that we've put together allows us to purchase the Assets in the building lease the the building and the land back from the the Kennedy Innovation Center and then focus on making syringes for nefron beginning at the end of Q2 and 25 and then with the restructured sales agreement which is 5 years uh for three
different products that will total more than 200 million in sales for sharps over that time period it allows us to have um ramp up capacity to um support um surge production for nefron but also support some of the other large healthc care companies in the US that have approached us so while we were reworking the deal uh with nefron um then at the beginning of this year um we had some of the most prestigious healthcare companies in the United States approach us about partnering with them to make pre-filled co-polymer syringes for them so uh on
the conclusion of the purchase of the building and the signing of the documents we'll be in a position to announce another major customer who will be partnering with us to help bring that facility online to supply here in the United States so we're really excited about it the the the mix of products is a better overall mix for us it still helps nefron achieve all of their goals and then it allows us to really become a strategic player for the co-polymer syringes across the United States not just in nefron but other major drug uh manufacturing
companies here in the US has has the Hungary facility started to see any any activity in terms of potential sales absolutely we um we'll be shipping out our first order to South America partnership that we formed over the last couple months um this is an opportunity for us to introduce uh our our secure guard products there um that are approved by the World Health Organization so the South American Market really needs um technology that focuses on reuse prevention to minimize the risk of of of disease transmission through the ReUse of syringes that takes place today
so part of what's happening for us with um key um opportunities within South America our partner is going to get our products qualified and then there'll be a transition from the standard syringe into the secure guard uh safety syringe which will allow us to use our technology to help the Health Care System there in South America so we're pretty excited about that we've also had um large government um opportunities over the last couple weeks as a result of this Chinese um news that they've reached out to us to begin qualification for some of the secure
guard products uh for them so um the opportunities are definitely uh increasing the the interest in the products is is definitely increasing I've been on a handful of calls myself with potential partners that want to look at what we can make for them how we can make it how fast we can make it so we're looking through those opportunities now and uh we're pretty excited about the Future 4 hungry you know just just give everybody a little refresher how long you been in this industry Robert yeah I've been in the industry for more than 25
years I've had the opportunity to work for um most of the major pharmaceutical and medical device packaging companies that are out there um and most of the major healthc care companies so you know my my resume includes uh bigger companies like like Baxter Healthcare Boston Scientific uh gimer a few others like Alcan pharmaceutical packaging um so I've had the opportunity to either work with all of the Branded pharmaceutical customers including fiser MC um AB the you know many of the others either as a customer or as a partner or as a as an employee so
having these relationships with these these these companies that are looking for better sources of of packaging and devices to help deliver their their drugs and their technology to to the the Health Care system is is is a great opportunity for us so you know being in this industry a long time I I've worked with um a lot of the packaging companies like I mentioned and you know I understand how they think you know what their strategies are what they're looking to do and then that just allows me to kind of you know refocus repurpose sharps
in a way to carve out the space that that we want to create for ourselves uh for the you know the the smart safety syring technology and then the the pre-fill syringes that we're going to talk about later so those two spaces are really nice spaces for us we have a lot of expertise in those areas uh there are high growth uh high margin uh areas especially on the pre-field syringes so you know this is going to be a nice little opportunity for us to to kind of form the what I would say the the
Cornerstone of the business here in South Carolina so we're we're excited about it so 35 35 million to purchase the building and equipment that is there yeah so we're going to purchase the assets I want to be clear and then we're going to lease the building um from the Kennedy Innovation group there with the opportunity to purchase the land in the building uh when we're ready to do that so the the lease has been negotiated very favorable for us it's in a it's in a taxfree tax benefit area in South Carolina for the kennedies so
we agreed to do a partnership where you know we're going to run the building we're going to manage the building and the land um through a lease and then they're going to be our partners kind of like our landlords if you will for the operation until we're ready to buy it or until they're ready to sell it so we have a very um like I said favorable lease that has a lot of terms to it that allows us to extend the lease as we need to or move into a purchase situation when it's right for
them and for us so you know I I know that that everybody's let let's let's let me ask you this question sure how much cash do you have on right now uh a couple million okay so everybody is going to be sitting there going how in the hell are they going to buy a $35 million business if they only have a couple million bucks does that mean that they're going to get diluted the out of well the the way we're going to approach it is we have through this rework deal um identified a strategic partner
who's going to come in and be a part of what we're going to do so we're not prepared to to say a lot about that yet um it'll be part of us working this deal with with the purchase of the facility but the the opportunity to have a strategic partner who's going to bring in a large part of the funding to help us get this done will hopefully you know allow us to create some moment and then raise the additional money there there's a couple different ways you can do it you know you can you
can you know raise money through the through the company through the stock um you know it can create dilution but you can also do it through debt you can do it through other ways so we have some opportunities in front of us that we're reviewing um going through to to be smart about how we do it so currently you know the the upside is we have no debt right so the ability to do things is is is very easy for us um with with this sales agreement of of more than $200 million over five years
it gives us a lot of Leverage from the standpoint of of how we're going to you know raise money you know obtain money to do what we're going to do but we're we're very confident we can do it um and you know the people that are backing me around this are more than excited about the deal uh and they've actually approached us about being a part of the deal so you know that's what I think makes this different is you know we have the support of the k ities you know we have the support of
Black Rock the the the main the Main Financial um adviser for for nefron and then we have our strategic partner who's who's going to be a big part of this so you know this will all kind of come out um here soon and we'll talk about it more but um you know we're excited that we have the opportunity the sales agreement is key and then the ability to raise the money to to get this facility you know 35 feels like a lot but when you think about what we're going to get and and what it's
going to do it it's huge because that 200 million just from nefron over five years is more than 40 million in Revenue so when you you tack on the other customers that I was talking about it takes us well over 5060 million a year run rate you know just with those two or three customers for that facility so these are very profitable products you know you're sitting somewhere in the the 40 to 80% margin depending on the sizes and the configurations of the pre-filled syringes so you know when you look at the news in addition
to what we're trying to do you know shot pharmaceutical packaging uh just to grab some news that came out you know a month or so ago is committing $350 million to a green field in North Carolina to make similar type products both in the co- polymer and the glass because they're that committed to the industry with these Technologies so you know building a green field that big with that kind of money you're looking at 3 or four years before they have most of that going for us to pick up you know a facility that is
100 100,000 square feet that can generate that has the potential to generate more than a hundred million do in Revenue once it's fully built out you know with margins in the 40 to 80% you know and it's strategically located in South Carolina near the Research Triangle for most of the major drug companies on the East Coast you know 35 million is is very little money you know compared to what shots going to do 35 million if um is the is the building and the equipment ready to go I mean or or is there additional cost
that that need to be incurred yeah to get us going most of all the equipment is there we have to finish building out the the the Str the the setup of the line so you know the the the the the techn techology is all there so the first the first two manufacturing lines the 10 mL and the 50 ml are pretty much set up you know we need we need about 8 to 10 months worth of work to finish the the setup of the inside of the facility so all the material handling all the infrastructure
the electrical the power the HVAC the floor everything is good to go we need to just kind of build out um the support systems and then finish the validation work work that's been started by my team uh in support of nefron to to make this operational so it'll take about 8 to 10 months before we begin to ship product from our first line so that's where you know we you know we have some challenges but you know working inside the facility side by side with um the the people for inject EZ that are part of
nefron you know we we understand everything that's inside the facility so there's no surprises for us you know we've got a very detailed project plan on on how we're going to get this done we've got resources identified to come in and help us get us done uh we've got industry experts that are tied to this already who've given us feedback on the equipment the technology and you know what what the opportunities are going to be and what some of the challenges will be so we're we're we're very prepared is the best way I can say
it around getting the plant operational in in under 10 months okay so how do you have a dollar amount of how much it would cost to get get it to where you want it to be yeah so the the the plan will start up in phases so you know it's going to take um you know probably close to another 10 million to get the first two lines finished up and so that's where the Strategic partner coming in you know we're going to buy the facility we're going to get the first two lines up and going
get the plant set up everything will be qualified through that money and so you know looking at 35 Plus another 10 uh you know plus some operating Capital to allow us to to start to bring people in and train them so you know you're looking at around 50 million from the standpoint of what we want to do to to make that plant ready to go for the first you know probably 30 million 35 million pieces but Hungary is set right Hungary is set the the opportunity um that's there for hungry like we talked about if
if one of these contracts um kicks in you know South America you know one of the the government agencies that we're working with in Europe you know it could consume most of the capacity so the the beauty of Hungary is there's no debt um you we we paid it we paid for it in cash when we did the IPO but the facility is expandable so the facility right now is about 40,000 square ft but we own land around the building and it would be easy to expand the the operation to create capacity and then the
technology partner that we have to bring in some new high-speed assembly equipment and molding uh equipment would be have already been identified we've been in talks with them around these opportunities so you know it would be easy to ramp up the facility first 40 million pieces and then expand the facility to probably close to 100 million pieces over the next couple years okay all right so the capacity right now as it exists today is is how many somewhere between 40 and 50 million depending on mix okay so these are the smart safety syringes these are
the plastic syringes they're not the pre-filled syringes that we're going to make in South Carolina so there's two there's two different uh product families okay okay but still I mean if you've got some sales starting to kick in there that can help for sure yeah absolutely okay so um how many shs outstanding right now fully diluted Robert um it's changing a little bit so you're um probably 15 to 17 million I can get a current number for you so it's it's still very low yeah it's very low so when you look at the the floats
you look at the the opportunities for us you know even if we're going to raise some money through shares based on the news and what's going to happen with the company you know the opportunity for us to do that quickly is is going to be there so as this news gets out and people start to understand you know we're looking at about 15.7 million shares outstanding you got a public float of about 14 million shares is what I'm seeing today so um you know it's it's small that's part of the challenge for us is creating
the opportunity uh for the company getting people to understand what we can do and that's where you know this this deal with nephron that's going to not only help nefron but help us um having having black rocks blessing on this as it's huge for us yeah yeah yeah okay um there's a lot of lot of pieces here right yeah there's a lot of pieces it's a it's a big story uh you know like we talked last time there's been a lot of work that's gone into this uh you know we're very thankful for the opportunity
to to work with the kennedies on this deal um to create this opportunity they're very they're very Pro onshore um local Supply if they can get it so they really much Believe in Us manufacturing as much as they can for what they that what they do to help their business so you know to have the the first specialized co-polymer prefillable syringe plant in the US you know be ready to go in 10 months or less and then start shipping products and then we have some of the larger um what I would say Cornerstone uh healthc
care companies in the US reaching out to us to potentially Supply is just you know that that's just that's just additional news that that we weren't planning on but it's going to be great news for us but this little facility in South Carolina is actually expandable so the the plant itself is 100,000 square fet it can be expanded inside to produce somewhere close to 90 million pre-filled syringes but there's land next door that is owned by the kennedies that they're willing to sell to us if and when we need to expand so this little operation
could be easily 200 ,000 square feet and it could probably produce somewhere uh closer to 200 million syringes for the pre-fill syringe space for the market so you know you you know at even at 90 million pieces you're well over 100 million in Revenue you know by 28 so that's where you know some of these numbers I want people understand so the first 12 months of production just on the first few lines is going to generate north of 35 million in revenue and then you know 26 and you look at the calendar year of 26
being conservative this facility can make well over 50 million in revenue and then you get out to 28 with what we want to do with the the phased um startup and the expansion to the 80 90 million pieces you know you're north of $100 million in Revenue so for us being an early Revenue uh pre-revenue type company you know sitting at 15 million shares for us to have the opportunity to make a $100 million in Revenue by 28 with the margins we have is just is just huge and that's where that that is that including
Hungary numbers or no no that's just South Carolina yeah that's what I thought okay so you know what what what what could you what kind of run rate you think you get out uh I mean you know with with some of the other news that's going to come out um and Hungary and South Carolina I mean you're going to be well north of uh you know depending on how you want to look at it I mean you'll be north of a of a 130 $140 Million by 28 right so for me you know my goal
was to get here to to get hungry up and going you know this South Carolina opportunity with with nefron was you know kind of a a new opportunity but the the benefit is my team and myself have made these products before we know how to sell these products so you know the opportunity to have the the first plant is huge you know to to to bring a an opportunity that could generate $100 million in revenue for the company within four years I mean that's just unheard of for us for companies my size right that that
that would that that could quite possibly change lives oh it's definitely going to change lives I mean that's that's part of the reason I've been in the business so long and some of the people that I've brought over you know to work at Sharps you know from other companies that I've worked with in the past you know the the philosophy that we have is you know we want to we want to we want to change lives we want to make Health Care better safer for people that need it you know we want to transform the
industry where we can and bring better technology to to create these opportunities so you know when you when you have the right purpose purpose and you have the right people behind you and you have opportunities like this you know you have to take action to to make it happen so you know people need to look beyond the moment right now and look at what could be and you know how much we could really help the Health Care system and help people uh with our with our company and our products so it's that you just gave
me a perfect segue here so I I I think that it's important for people to understand I think actually uh consumers shareholders uh potential shareholders investors I don't think they they view that they can have as much impact as they actually can have right and there's this thing actually called impact investing and and I think it's so important for the the retail investor or public to understand that you know you can be part owner of Sharps you and by being part owner of Sharps you you are supporting something that maybe you believe you believe in
like improving the Health Care System right with safer products better quality of life right so that if that is Meaningful to you maybe because you have just have somebody that in your family has been dealing with Health Care issues or maybe you're dealing with healthare issues and you'd like to see those improvements instead of spending money on you know things that you don't really need like you know went out to dinner and spending a grand or whatever put it into the stock that you care about right that has an impact and I I think the
public is that's the beautiful thing about the stock market is they it gives you the ability to be part of something bigger than yourself right I mean these opportunities exist right now right now this stock is trading what what's the stock trading at right now yeah we got 80 cents yesterday on some of the 8K news uh right around 40 cents but as we start to release the news we expect that to change quite a bit so you know look if you have some patience yeah and I have to be very very clear about this
this is the kind of opportunity that you invest in you know this isn't something that I mean yeah you could probably make a nice little hit on a shortterm trade but that would be very narrow narrow thinking because if you're able to create what you just said which was 130 plus million run rate in four years the stock should reflect that okay and right now it doesn't I can tell you there it's not even close to reflecting that right so uh Robert so have you gotten the letter from the NASDAQ yet no we're working through
at I mean that's where we still have some time the you know the reality is you know that we we've been working on this deal to help lift the stock to create the certainty for the NASDAQ that you know we're going to be a company that's going to be here for a while right right so uh I mean let's see how long have you been below a buck yeah we've been below for a little bit um you know we had helped to close this close this deal last fall that was really the plan and then
you know we there was some challenges around the deal that were a little bit outside of my control like you and I talked about but you know I think with what's happened here and what we're about to do this deal is actually a better deal for us in a lot of ways and with this strategic partner and now that we have the support of Black Rock and the the kennedies you know it's it's just a matter of us executing so I think you know some people are going to wait till we close on the deal
uh some people are going to get in now and benefit so you know there's there's lots of opportun unties this is this is the type of stock you want to you want to hold for some time because the upside is so great you know that's where you know you and others are going to help me tell the story you know micro caps like this just don't walk into a a $200 million deal over five years you know with an opportunity to make products that can change people's lives it's a it's a great opportunity it's a
great story with it with with the building that's already built that's already got equipment in it yep I mean it's just it's really almost amazing right I mean it is this is like a uh serendipitous moment right you've got the China issues the tariffs doesn't matter who winds up being in office uh for the next four years because if it's Biden well that 50% tariff isn't going anywhere and if it's the other guy it might go up to 100% who knows right so I think that this is a just like the perfect storm for you
yeah I me we we've actually talked to some of these companies that have been called out by the FDA they've reached out to us to have conversations around different potential strategies and I can tell you you know being on the phone with these these these different companies in different ways they're very nervous around how all of this is going to impact their business and and what's going to take place so you know the the opportunities for for companies that can take advantage of this the timing you know for a lot of the the the non-chinese
products like what we make um is is huge and then you know to have this opportunity here to grow this industry for pre-filled syringes you just makes it better so we've always wanted to kind of play in both spaces um since I got to the company and so both opportunities now you know feel really strong to me from the standpoint of the the plastic smart safety syringe technology and the pre-fill syringe technology so we're going to definitely try to take advantage of both it this has been a this has been a um you feel like
you've learned a lot Robert oh yeah I mean it's been a it's been a life-changing opportunity for me personally you know I've worked in the industry for a long time like we talked about I had the the benefit of working for a lot of really strong managers uh in my time directors presidents but I also had the opportunity to work for some that weren't so great so you know there's always something to learn you know you learn what to do and then you learn what not to do and then you know I always told myself
when I got to a place where I could really Drive change I wanted to bring the I wanted it to be you know for the right reasons to bring the change and then I wanted to bring the right people in and then run it the way that it needs to be managed and so you know I'm thankful for a lot of those uh life-changing opportunities that I had but to be actually in the role you know leading the company through the IPO through all of this transition and now you know to to be able to
close on this deal and and really change our company which is going to allow us to change people's lives and really help the US healthc care industry uh you know it's just too good of an opportunity to pass up it's been a lot of long hours it's been a lot of uh time working with people that have helped me get to this point so I'm very thankful for that but definitely a life-changing uh event for me for sure yeah and and this is uh this is this is I think could be this could be a
real feather in your C man yeah and I know that this has not been an easy this has not been an easy Journey you've had to pull a lot of rabbits out of a lot of different hats right I mean yeah yeah we have and it's you know my career for the most part you know it's it's always been about helping other people you know whether it's my PE group or others within the company to be successful so that's still always been my philosophy so when you when you learn more about our company and how
we do things I give a lot of latitude and support to my direct staff and and people below them to to make the right decision because I trust these people to do the right thing because we've worked together you know in the past so many different times you know we we we have the same philosophy we have the same approach so I'm very thankful for the team that I have and then the the people that have reached out to me that's the remarkable thing I have had so many people reach out to me from my
past about wanting to be a part of Sharps and how can they be a part of Sharps and so I've told them to to be patient and until we had the right opportunity but you know when people from your past you know not just the last company but companies several back you know are reaching out to you to work with you and and to to drive help support drive your driving your vision and your strategy you know that's that's very reassuring that you're you're headed down the right path you know why you're a likable guy
I mean you really are a likable guy you come off is very genuine and transparent and you're just a likable guy I mean you're the kind of guy that you want to root for at least I think you know you're the kind of guy that you this is your first rodeo as CEO as the as the shot caller right and and you've been in the industry a long time you've done I'm sure some good things for a lot of people over your 25 years and that's that's coming back it's it's coming back to you now
that's that's the way I see it yeah and I I mean you know it's I've had a lot of people helped shape you know my my career and my past and like I said I've learned from a lot of people so i' I've had a lot of support and you know I've had a lot of personal things that have changed my life and how I view things and and what I would do you know now that's different from before so you know my my parents you know the friends I've had the you know my faith
you know a lot of that's played into all that you know and so to have this opportunity again I keep saying it I mean this you just don't you just don't you just don't find this very easily I mean I've been in the industry like I said for more than 25 years so to be here be now doing this you know with everything going on in the industry and then this opportunity here to help nefron and others with these specialized products is just it's just too good to pass up I mean it's it's set up
for us to execute now so when when do you think Robert when do you think we'll maybe have some clarity on the the the partner and I mean how how how what kind of a window are you looking at in terms of time frame yeah so we we have 60 days from when we sign the documents to execute the the purchase uh we'll be announcing some things between now and then so just so everybody knows I mean we actually signed the documents um last Monday um and then we announced the 8K on Friday and then
we were waiting to this week because of the holiday to announce all the all the press and be able to talk about it because you know Wall Street was shut down on Monday and it was a holiday for a lot of people so you know we were a little bit strategic to work around the holiday but you know the plan is to you know work with you Tim and others we have red chip and a few others that are going to help tell the story so as we as we make progress and and we start
to execute against some of the milestones for the project we'll be updating everybody on how that's coming along okay perfect and when we get real full-blown Clarity yeah let let's have you back for a you know a real quick rundown on on everything yeah for sure I mean I the the press release that'll be coming out and then some of the information that's out there you know we uh we try to be as clear as we can we're putting together not only a press release but an investor letter that'll kind of explain things and what
it means for us um and so we're we're going to try to put as much written communication out there as we can that what does that mean to the people watching sign up for investor relations email alerts today do that today y because I gotta I have a feeling that there's going to be a lot of news flow coming that way for sure right yep for sure that's the yeah Robert I'm so excited for you man because I know I know the challenges that challenges that you've been facing and you are um you're committed man
I mean he's stuck in there we so I mean you and I had many conversations good and bad you know be back on your show being able to tell you and and your your team and people that follow you that you know we were able to overcome that and get to this point I I think is a is a great great story around perseverance and and you know taking advantage of of opportunities and and hard work so we're again thankful to the Kennedy for giving us this opportunity and and and for Black Rock to support
us through this through this deal so that's gonna be great that's awesome it's just awesome congratulations Man I mean there's still a lot of work to be done but yep it definitely looks like things are heading in the right direction so sure yeah so thanks Tim appreciate your time and yeah bet go ahead anything else that you feel as though I missed no I mean the I think the the big news is the the focus on South Carolina you know we have more than one strategic customer that'll be forthcoming you know the opportunity to take
this company from early Revenue to 50 million in a few years and then 100 million in four years and then the the Strategic partner that we're going to tell the market more about here over the next few weeks I mean that's going to turn us into a global a global a global company I mean we're going to have multiple facilities across the globe that will allow us to execute a lot of the strategy that that we've been putting together so this is just one piece so this inject EZ operations really just one piece for what
we're going to try to announce over the next um four to six weeks ah awesome all right Robert I can't wait to see uh can't wait to see what comes next thanks man appreciate your time and uh definitely once we get closer to announcing some new news I I'll reach out to you we can update everybody all right thank you for tuning in to another CEO follow-up interview here at alpha wolf trading today we have Robert Hayes from Sharps Technologies Inc ticker symbol stss I hope you enjoyed today's interview and if you did do us
a favor give us a like how about giving us a share while you're at it make sure you smash that subscribe button these things are very important to us and we appreciate you taking the time to do that until next time stay safe alpha wolf trading wishes you the very best of success